Cyclo Short Term Debt from 2010 to 2024

CYTH Stock  USD 0.73  0.03  4.29%   
Cyclo Therapeutics' Short Term Debt is increasing with slightly volatile movements from year to year. Short Term Debt is estimated to finish at about 2.4 M this year. For the period between 2010 and 2024, Cyclo Therapeutics, Short Term Debt quarterly trend regression had mean deviation of  704,896 and range of 2.4 M. View All Fundamentals
 
Short Term Debt  
First Reported
2000-09-30
Previous Quarter
M
Current Value
20.1 K
Quarterly Volatility
413.3 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.3 K, Interest Expense of 181.7 K or Total Revenue of 995.2 K, as well as many indicators such as Price To Sales Ratio of 25.33, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cyclo Therapeutics Correlation against competitors.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Latest Cyclo Therapeutics' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Cyclo Therapeutics over the last few years. It is Cyclo Therapeutics' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Cyclo Short Term Debt Regression Statistics

Arithmetic Mean609,640
Geometric Mean155,152
Coefficient Of Variation146.63
Mean Deviation704,896
Median131,512
Standard Deviation893,943
Sample Variance799.1B
Range2.4M
R-Value0.64
Mean Square Error507.9B
R-Squared0.41
Significance0.01
Slope127,967
Total Sum of Squares11.2T

Cyclo Short Term Debt History

20242.4 M
20232.3 M
2022M
2021153 K
2020131.5 K
201616.4 K
2015754 K

About Cyclo Therapeutics Financial Statements

Investors use fundamental indicators, such as Cyclo Therapeutics' Short Term Debt, to determine how well the company is positioned to perform in the future. Although Cyclo Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Short Term Debt2.3 M2.4 M

Currently Active Assets on Macroaxis

When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:
Check out the analysis of Cyclo Therapeutics Correlation against competitors.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.046
Quarterly Revenue Growth
0.051
Return On Assets
(2.82)
Return On Equity
(226.64)
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.